Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response

Glioblastoma multiforme (GBM) is the most common and most aggressive type of primary brain cancer. Since median overall survival with multimodal standard therapy is only 15 months, there is a clear need for additional effective and long-lasting treatments. Dendritic cell (DC) vaccination is an exper...

Full beskrivning

Bibliografiska uppgifter
Huvudupphovsmän: Dejaegher, Joost, Van Gool, Stefaan, De Vleeschouwer, Steven
Materialtyp: Online Artikel Text
Språk:English
Publicerad: Dove Medical Press 2014
Ämnen:
Review
Länkar:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918234/
https://www.ncbi.nlm.nih.gov/pubmed/27471700
http://dx.doi.org/10.2147/ITT.S40121

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4918234/
https://www.ncbi.nlm.nih.gov/pubmed/27471700
http://dx.doi.org/10.2147/ITT.S40121

Liknande verk